Zacks Research Has Negative Forecast for ESPR Q3 Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 12th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.02) for the quarter, down from their previous forecast of ($0.01). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at ($0.28) EPS.

A number of other research analysts also recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, February 11th. Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price on the stock. JMP Securities restated a “market outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Finally, StockNews.com downgraded shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $1.86 on Monday. The stock has a market capitalization of $366.49 million, a price-to-earnings ratio of -2.91 and a beta of 1.01. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The company’s 50-day simple moving average is $2.18 and its 200-day simple moving average is $2.11.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company acquired a new stake in Esperion Therapeutics in the 2nd quarter valued at approximately $159,000. SG Americas Securities LLC increased its holdings in shares of Esperion Therapeutics by 105.9% during the third quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 39,635 shares during the period. Traphagen Investment Advisors LLC acquired a new position in shares of Esperion Therapeutics during the third quarter valued at $27,000. Versor Investments LP bought a new stake in shares of Esperion Therapeutics during the third quarter valued at about $44,000. Finally, Summit Wealth Group LLC acquired a new stake in Esperion Therapeutics in the third quarter worth about $66,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.